BioRestorative Therapies, Inc. (NASDAQ:BRTX) Short Interest Up 197.0% in March

BioRestorative Therapies, Inc. (NASDAQ:BRTX) was the recipient of a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 19,900 shares, a growth of 197.0% from the February 29th total of 6,700 shares. Based on an average daily trading volume, of 454,500 shares, the short-interest ratio is presently 0.0 days. Approximately 0.6% of the company’s shares are short sold.

BioRestorative Therapies Stock Performance

BRTX opened at $1.40 on Thursday. The firm’s 50 day moving average is $1.51 and its 200-day moving average is $1.72. BioRestorative Therapies has a 52-week low of $1.20 and a 52-week high of $7.13.

Insider Activity at BioRestorative Therapies

In other BioRestorative Therapies news, major shareholder Dale Broadrick purchased 86,041 shares of the business’s stock in a transaction that occurred on Friday, February 9th. The shares were purchased at an average price of $1.32 per share, for a total transaction of $113,574.12. Following the completion of the acquisition, the insider now owns 477,972 shares of the company’s stock, valued at approximately $630,923.04. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 21.60% of the stock is currently owned by insiders.

Institutional Trading of BioRestorative Therapies

Hedge funds have recently made changes to their positions in the company. FNY Investment Advisers LLC purchased a new stake in shares of BioRestorative Therapies during the third quarter valued at approximately $26,000. Lynwood Capital Management Inc. acquired a new stake in shares of BioRestorative Therapies during the third quarter worth approximately $36,000. Finally, Vanguard Group Inc. grew its position in shares of BioRestorative Therapies by 8.6% during the third quarter. Vanguard Group Inc. now owns 137,818 shares of the company’s stock worth $247,000 after buying an additional 10,862 shares in the last quarter. Hedge funds and other institutional investors own 69.38% of the company’s stock.

About BioRestorative Therapies

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.